Brazil's medical establishment splits over hormone implant restrictions

Brazil's medical establishment is fractured over a question that affects millions of women: who gets to decide when hormone implants are medicine and when they're vanity? The Conselho Federal de Medicina, the country's federal medical council, drew a line in 2023. Hormone implants—small pellets inserted under the skin to deliver steady doses of hormones—are now forbidden when the goal is cosmetic enhancement, muscle gain, or athletic performance. But the restriction has opened a chasm between those who see the ban as necessary protection and those who warn it will leave chronically ill women without treatment.

The CFM's position is straightforward. The council says manipulated hormone implants, prepared individually in compounding pharmacies rather than manufactured industrially, bypass the rigorous testing, quality control, and monitoring required of approved medications. Without those safeguards, the council argues, no one knows how much hormone enters the bloodstream daily, how long it stays active, or what damage it might cause over years. The ban targets what it calls unjustified uses—testosterone prescribed without proof of deficiency, hormones marketed as "bioidentical" or "nano" without scientific evidence of superiority, and a class of drugs called SARMs. The council insists the restriction does not touch legitimate medical treatment. Endometriosis, adenomyosis, menopause, and other recognized conditions can still be treated with hormones when diagnosis and clinical need are clear.

But the ground beneath that distinction is unstable. Endometriosis—a chronic inflammatory disease in which tissue grows outside the uterus, causing severe pain and infertility—affects between 5 and 15 percent of Brazilian women of reproductive age, roughly 10 million people. Diagnosis takes three to eight years on average. A survey by the Ipsos Institute found that 77 percent of women with endometriosis have had their symptoms minimized or dismissed by healthcare providers. Gynecologists were named as a source of invalidation by nearly a third. Almost half were told their pain was stress or fatigue. The same survey revealed a stark divide in access: while half of public health system patients received birth control pills as treatment, two-thirds of private patients did. For more complex procedures like laparoscopic surgery, the gap widened—20 percent of public patients versus 55 percent of private ones.

Into this landscape of delayed diagnosis and unequal care came manipulated hormone implants. For many endometriosis patients, especially after an industrialized medication was discontinued, these compounded implants became a lifeline. Now the FEBRASGO, the Brazilian Federation of Gynecology and Obstetrics Associations, one of the country's oldest and most influential medical bodies, maintains its position against them. The federation's president, Maria Celeste Osorio Wender, emphasized that the implants lack the safety data that approved drugs must provide—no studies showing absorption rates, peak hormone levels, duration of effect, or long-term clinical outcomes. "We have no studies showing clinical efficacy," she said.

On the other side stands the Sociedade Brasileira de Medicina Personalizada, the Brazilian Society of Personalized Medicine, which argues the debate has strayed from aesthetics into territory that threatens patients with chronic disease. The society contends that roughly 10 million Brazilian women with endometriosis face losing access to treatment. Its president, Walter Pace, framed the conflict sharply: unethical doctors using hormones for cosmetic purposes should not become an excuse to punish women suffering from chronic illness. An endocrinologist with the society, Guilherme Renke, went further, calling the restriction an abandonment of global scientific consensus and patients' right to personalized medicine. The society has also raised the possibility of economic interests at play—suggesting that resistance to implants might protect market share for established pharmaceutical companies.

Meanwhile, the restriction exists largely on paper. The CNN Brasil reporting team found videos on public social media profiles in which doctors continue to promote hormone implants for performance, energy, libido, and body composition. The Agência Nacional de Vigilância Sanitária, Brazil's drug regulatory agency, did not respond to requests for comment. What emerges is a system in tension: a medical council trying to prevent abuse of unregulated compounds, a medical establishment divided over whether the cure is worse than the disease, and millions of women caught between a diagnosis that takes years to confirm and a treatment that may soon be unavailable.